Leadership team promotion announcement by Ability Biotherapeutics

We are proud to announce the promotion of Dr. Patricia Giblin to Chief Science Officer and Dr. Jean-Philippe Bürckert to Chief Technology Officer. These promotions reflect the growing scope of their leadership and their critical contributions to our mission.

These well-deserved promotions mark more than individual achievements. They signal a major transition for our company. What began as a next-generation antibody platform is now evolving into a clinical-stage biotech, with human trials on the near horizon.